Viral contaminations are rare events in biopharmaceutical manufacturing, but regulatory agencies expect all biologics to undergo viral clearance testing to mitigate the risk of contamination [1, 2]. Therapies based on viral vectors have a small …
The article discusses the reasons behind the growing need for viral vectors and how Biovian, as a CDMO has taken actions to solve the manufacturing bottleneck. Antti Nieminen, CEO of Biovian: “The majority of Biovian’s customers …
Outsourcing as a business model within the Life Science-industry is growing year by year. Choosing the right contract development and manufacturing organization (CDMO) has become an important factor for the success of drug product development. …
The whys and the whats of GMP production of biopharmaceuticals. Why’d you have to go and make things so complicated? This chorus of the pop-rock song, Complicated, may reflect the thoughts of drug developers when …
The leading regional newspaper of of the Southwest Finland interviewed Knut Ringbom, the CEO of Biovian about the COVID-19 vaccine manufacturing possibilities. “Pandemic vaccine manufacturing is a hot topic. We have been contacted by European …
GEN, one of the biggest biotech magazines interviewed Biovian about the critical bottlenecks in Adeno-associated virus (AAV) Manufacturing. AAVs, gene therapy and manufacturing technologies are two of the “hottest” biotech areas in the industry right …
Adeno-associated virus (AAV) has emerged as the most flexible and useful vector for gene therapy. With hundreds of gene therapy trials ongoing, safe and efficient production of AAV is absolutely critical. In this roundtable discussion, …
We are pleased to let you know that Magnus Gustafsson from Biovian will speak about New Biologicals at “New Horizons in Biologics & Bioprocessing digital event”, on December 17th at 8:45 (CET). TALK: Manufacture and …
Discussion with Scientist Pekka Puolasmaa and Project Manager Tuomas Nikula. The goal of gene therapy is to treat or cure severe diseases by carrying genetic material to the target cells to repair the incorrect or …
In this video the CEO of Biovian, Knut Ringbom, presents an overview of the year 2020, especially discussing the latest developments in the company. “Over the last year, we have experienced a lot of positive …